Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:2013:739029.
doi: 10.1155/2013/739029. Epub 2013 Apr 11.

Efficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials

Zongguo Yang  1 , Liping Zhuang, Lei Yang, Xiaorong Chen
Affiliations

Efficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials

Zongguo Yang et al. Gastroenterol Res Pract. 2013.

Abstract

Background. The efficacy and tolerability of peginterferon α -2a and peginterferon α -2b in chronic hepatitis C (CHC) patients remain controversial. Methods. PubMed, Ovid, and Cochrane libraries were electronically searched until August 30, 2012. Studies that met the inclusion criteria were systematically evaluated by two reviewers independently. Results. The overall sustained virologic response (SVR) rate of the peginterferon α -2a group was significantly higher than that of the peginterferon α -2b group (46.7% versus 42.4%, P value = 0.01). The same tendency was observed for naïve, genotype 1/4, and genotype 2/3 patients. The early virologic response (EVR) and end-of-treatment response (ETR) rates were significantly higher in the peginterferon α -2a group than in the peginterferon α -2b group (56.1% versus 49.8%, P < 0.0001; 67.9% versus 56.6%, P < 0.00001, resp.). Peginterferon α -2a had a significantly lower discontinuation rate than peginterferon α -2b (27.9% versus 33.9%, P < 0.0001) in naïve patients. In both naïve CHC and hepatitis C virus genotype 1 patients, peginterferon α -2a had a higher relapse rate than peginterferon α -2b. Conclusions. Peginterferon α -2a has superior efficacy with higher EVR, ETR, and SVR than peginterferon α -2b for CHC patients, both plus ribavirin. Peginterferon α -2a might obtain a similar or even lower discontinuation rate than peginterferon α -2b. However, peginterferon α -2a had a higher relapse rate than peginterferon α -2b.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Risk of bias assessment.
Figure 2
Figure 2
SVR rates of chronic hepatitis C patients who received the two regimens of peginterferon α-2a and peginterferon α-2b, both plus ribavirin.
Figure 3
Figure 3
The RVR, EVR, and ETR rates of CHC patients treated with the two regimens.
Figure 4
Figure 4
The discontinuation rates and drugs modification of CHC patients who received the two regimens.
Figure 5
Figure 5
The relapse rate of CHC patients who received the two regimens.
See this image and copyright information in PMC

References

    1. Omata M, Kanda T, Yu ML, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatology International. 2012;6:409–435. - PubMed
    1. European Association for the Study of the Liver. EASL clinical practice guidelines:management of hepatitis C virus infection. Journal of Hepatology. 2011;55(2):245–264. - PubMed
    1. Seeff LB. The history of the “natural history” of hepatitis C (1968-2009) Liver International. 2009;29(supplement 1):89–99. - PMC - PubMed
    1. Schaefer EAK, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology. 2012;142:1340–1350. - PubMed
    1. Yenice N, Mehtap O, Gümrah M, Arican N. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turkish Journal of Gastroenterology. 2006;17(2):94–98. - PubMed

LinkOut - more resources